Beyond a single pathway: combination therapy in pulmonary arterial hypertension
Why the study?
Does combination therapy improve long-term outcomes and delay disease progression in patients with pulmonary arterial hypertension?
Population
Patients with pulmonary arterial hypertension (PAH)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support sequential or initial dual combination therapy in PAH; leaves open optimal triple-pathway regimens for randomized confirmation.
Structured PICO
Does combination therapy improve long-term outcomes and delay disease progression in patients with pulmonary arterial hypertension?
P
Population
Patients with pulmonary arterial hypertension (PAH)
I
Intervention
Combination therapy (dual or triple therapy targeting key pathways: phosphodiesterase-5 inhibitor, endothelin receptor antagonist, prostacyclin pathway)
O
Outcome
Long-term outcomes and disease progression
Combination therapy targeting multiple pathways is increasingly recommended for all patients with pulmonary arterial hypertension to improve outcomes and delay disease progression.
Cite This Study
Sitbon et al. (2016) studied this question.